Immuno-Oncology Translation Network: Data Management and Resource-Sharing Center at RPCI

免疫肿瘤学翻译网络：RPCI 的数据管理和资源共享中心

• 批准号: 10175624
• 负责人: Alan David Hutson
• 金额: $ 84.1万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-30 至 2023-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10175624
• 关键词: Address; Atlas of Cancer Mortality in the United States; Awareness; Bioconductor; Bioinformatics; Biometry; Biostatistics Shared Resource; Buffaloes; Cancer Center Support Grant; Catalogs; Clinical; Collaborations; Combined Modality Therapy; Communication; Communities; Comprehension; Comprehensive Cancer Center; Computer software; Computing Methodologies; Data; Data Analyses; Data Analytics; Data Management Resources; Databases; Dependence; Development; Drug Kinetics; Drug resistance; Education and Outreach; Ensure; Fostering; Funding; Goals; Hand; Immunooncology; Immunotherapy; Informatics; Information Technology; Infrastructure; Intranet; Logistics; Malignant Neoplasms; Manuscripts; Methods; Multiomic Data; Oncology; Performance; Policies; Positioning Attribute; Preparation; Principal Investigator; Procedures; Productivity; PubMed; Records; Reproducibility; Research; Research Design; Research Personnel; Research Project Grants; Resistance; Resource Sharing; Resources; Structure; Supercomputing; System; Text; Training and Education; Translations; United States National Institutes of Health; Universities; anti-cancer therapeutic; biobank; bioinformatics tool; cancer therapy; combat; data harmonization; data integration; data management; data repository; data sharing; data tools; design; drug sensitivity; expectation; experience; high standard; improved; innovation; interest; member; metabolomics; multidisciplinary; multiple omics; open source; operation; outreach; predictive marker; protocol development; quality assurance; real time monitoring; resistance mechanism; response; social media; support network; translational study; tumor; web portal

This application is being submitted in response to the Notice of Special Interest (NOSI) identified as NOT-CA- 20-052. Project Summary While several innovative and creative anti-cancer therapies have shown promising results, a significant expansion of their clinical use will require collaborative efforts to elucidate resistance mechanisms, exploit tumor sensitivity, map cancer dependence, discover new targets, identify predictive biomarkers, evaluate combination therapies, and develop real-time monitoring approaches. Leveraging cutting-edge multi-disciplinary team approaches, we will support the NCI Drug Resistance and Sensitivity Network (DRSN) to understand and combat mechanisms of tumor resistance and to exploit tumor sensitivity to anti-cancer therapies. Our strategy is to serve as an administration, communication, collaboration and analysis hub to coordinate the DRSN’s network-wide studies, focusing on reducing barriers to domain expertise, improving the productivity of DRSN investigators, maintaining a high standard for data harmonization and integration, designing and implementing rigorous analytical strategies, and fostering a collaborative and supportive research community. An experienced, multidisciplinary team has been assembled to pursue five Specific Aims: First, we will provide a centralized administration infrastructure to coordinate DRSN activities, building upon the Immuno-Oncology Translational Network (IOTN) Data Management and Resource-sharing Center (DMRC)’s well-functioning infrastructure that currently coordinates network studies under the umbrella of the NCI Cancer Moonshot initiative. Second, we will actively promote the DRSN and foster trans-consortium interactions, where we will leverage the IOTN DMRC’s demonstrable experience in Cross-Moonshot outreach and Bioconductor’s decades-long record in community-wide engagement. Third, we will provide multidisciplinary expertise to support DRSN collaborative research, leveraging four of the Roswell Park CCSG’s shared resources: Biostatistics, Bioinformatics, Data Bank and BioRepository, Bioanalytics, Metabolomics & Pharmacokinetics. Our analytic support will be armed with professional IT staff and informed by an experienced anti-cancer therapeutic researcher team. Fourth, we will develop innovative multi-omics data integration methods to enhance DRSN’s research capacity, capitalizing on the well-respected and highly-successful Bioconductor project. Fifth, we will disseminate resources developed in the DRSN to the broader community, unleashing the full potential of DRSN activities. Taken together, we envision our CC, in close collaboration with the DRSN components, will allow us to conduct highly effective and innovative translational studies to address the significantly unmet needs related to anti-cancer therapeutics, and fulfill the expectations and guiding principles of NCI Cancer Moonshot initiative.

本申请是为了响应被标识为NOT-CA的特别利益通知（NOSI）而提交的- 20-052. 项目摘要 虽然几种创新和创造性的抗癌疗法已经显示出有希望的结果，但一个重要的 它们的临床应用的扩展将需要协同努力来阐明耐药机制，利用肿瘤 敏感性，绘制癌症依赖性，发现新靶点，鉴定预测性生物标志物，评估组合 治疗，并开发实时监测方法。利用尖端的多学科团队 我们将支持NCI耐药性和敏感性网络（DRSN），以了解和打击 肿瘤耐药机制和开发肿瘤对抗癌疗法的敏感性。我们的战略是 作为管理、通信、协作和分析中心，协调DRSN的全网络 研究，重点是减少领域专业知识的障碍，提高DRSN调查人员的生产力， 保持高标准的数据协调和整合，设计和实施严格的 分析战略，并促进合作和支持性的研究社区。 一个经验丰富的多学科团队已经成立，以追求五个具体目标：首先，我们将提供 一个集中的管理基础设施，以协调DRSN活动，建立在免疫肿瘤学 翻译网络（IOTN）数据管理和资源共享中心（DMRC）的良好运作 目前在NCI癌症登月计划的保护伞下协调网络研究的基础设施 倡议第二，我们将积极推动DRSN，促进跨联盟互动，我们将 利用IOTN DMRC在跨月球探测器外展和生物导体方面的可证明的经验， 数十年来在社区范围内的参与记录。第三，我们将提供多学科的专业知识， 支持DRSN合作研究，利用罗斯威尔公园CCSG的四个共享资源： 生物统计学，生物信息学，数据库和生物库，生物分析学，代谢组学和药代动力学。我们 分析支持将配备专业的IT人员，并由经验丰富的抗癌治疗师提供信息 研究团队第四，我们将开发创新的多组学数据整合方法，以增强DRSN的 研究能力，利用备受尊敬和高度成功的生物导体项目。五是 向更广泛的社区传播DRSN中开发的资源，释放DRSN的全部潜力 活动总之，我们设想我们的CC与DRSN组件密切合作，将使我们能够 进行高效和创新的转化研究，以解决与 抗癌疗法，并履行NCI癌症登月计划的期望和指导原则。